How can you manage your company through recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified overarching themes.

Ernst & Young, along with the Economic Intelligence Unit, interviewed executives from leading global life sciences companies to learn how they remain competent.

As Washington changes direction, many question whether reform policies will present new opportunities or risks for the pharma, biotech, and medtech sectors.

It describes how the supply chain risks reaching peak levels amid global financial crisis.

Read our report to find out which 10 business risks are affecting the pharmaceutical industry worldwide.

The report represents broad perspectives from the industry and Ernst & Young on overcoming hurdles to developing innovative and safe products while managing financial performance.

This article discusses the implications of the new rules, which apply to transactions with closing dates on or after 1 January 2009.

This article describes challenges in supply chain management from variety perspectives including tax effectiveness, regulatory compliance, cost improvement, risk management, product distribution and safety.

This issue talks about exploring the current dynamics of the global financial crisis and its impact on the life sciences industry

This report talks about the challenges and opportunities facing pharmaceutical companies in four emerging markets: Brazil, China, Japan and Mexico.